Chronic heart failure patients with hypertension
Conditions
Interventions
administration of esaxerenone
Sponsors
Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with hypertension (systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure greater than or equal to 90mmHg) (2) Patients with chronic heart failure (NYHA functional classification I-III) (3) NYHA functional classification and receiving cardio-protective drugs such as ACE inhibitors, ARBs, or beta-blockers has been stable for 4 weeks from enrollment
Exclusion criteria
Exclusion criteria: (1) New onset of acute coronary syndrome, cerebrovascular diseases, myocarditis, constructive pericarditis, severe valvular heart diseases within 3 months. (2) New onset of atrial fibrillation or atrial flutter within 3 months (3) Severe kidney disease (eGFR less than 30 mL/min/1.73 m2 or dialysis patients) (4) Patients with hyperkalemia or serum potassium level>5.0mEq/L at enrollment (5) Patients erceiving potassium-conserving diuretics, mineralocorticoid receptor antagonists, potassium preparations (6) Cancer patients (7) Pregnant women, lactating woman or women who wish to a pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A change in E/e' between baseline and 6 months after the start of administration of esaxerenone. | — |
Secondary
| Measure | Time frame |
|---|---|
| A change in brain natriuretic peptide (BNP), left atrial volume index, left venrtricular mass index between baseline and 6 months after the start of administration of esaxerenone. | — |
Countries
Japan
Contacts
Public ContactHidekazu Tanaka
Kobe University Graduate School of Medicine Division of Cardiovascular Medicine, Department of Internal Medicine
Outcome results
None listed